Marvin Tankel, MD
Dermatology · Lynbrook, NYNPI 1700885290
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations.
Across 386 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$877
- Lilly USA, LLC$697
- Amgen$646
- E.r. Squibb & Sons, L.L.C.$604
- Novartis$599
- plus $4K from 22 others
What the payments were for
- Food & beverage$8,00697%
- Education$2803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $1,082 |
| Johnson & Johnson | 29 | $877 |
| Lilly USA, LLC | 31 | $697 |
| Amgen | 29 | $646 |
| E.r. Squibb & Sons, L.L.C. | 28 | $604 |
| Novartis | 27 | $599 |
| Sanofi | 21 | $541 |
| Regeneron Healthcare Solutions, Inc. | 17 | $510 |
| Almirall LLC | 25 | $408 |
| Galderma Laboratories, L.p. | 17 | $314 |
| Dermavant Sciences, Inc. | 18 | $298 |
| UCB, Inc. | 9 | $261 |
| Pfizer | 10 | $199 |
| Arcutis Biotherapeutics, Inc. | 9 | $180 |
| LEO Pharma Inc. | 11 | $175 |
| Helsinn Therapeutics (U.S.), Inc. | 7 | $160 |
| Biofrontera Inc. | 7 | $125 |
| Strata Skin Sciences, Inc. | 12 | $116 |
| Incyte Corporation | 4 | $91 |
| Botanix SB Inc | 4 | $74 |
| Boehringer Ingelheim | 4 | $73 |
| Sun Pharmaceutical Industries Inc. | 4 | $66 |
| Merz North America, Inc. | 2 | $47 |
| Dermira, Inc. | 3 | $46 |
| Organon | 2 | $39 |
| Verrica Pharmaceuticals Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $19 |
| Journey Medical Corporation | 1 | $14 |
How this compares
$8,286 in reported general payments places this provider in the 70th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Unoready PenSecukinumab | 14 | $168,944 |
| OtezlaApremilast | 20 | $88,541 |
| Dupixent PenDupilumab | 11 | $44,642 |
| Betamethasone Dipropionate | 153 | $5,352 |
| Clobetasol Propionate | 74 | $4,202 |
| MupirocinMupirocin Calcium | 11 | $3,157 |
| Metronidazole | 46 | $2,597 |
| Halobetasol Propionate | 47 | $2,179 |
| Ketoconazole | 98 | $1,675 |
| Triamcinolone Acetonide | 102 | $1,148 |
| Mometasone Furoate | 63 | $1,117 |
| Ammonium Lactate | 46 | $1,038 |
| Tacrolimus | 16 | $1,027 |
| Desoximetasone | 20 | $893 |
| Econazole Nitrate | 15 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $646 | $88,54120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,151 dermatology providers in New York.
Other dermatology in Lynbrook
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.